Welcome to our store!
New collections added on a weekly basis!
Now Accepting FSA & HSA cards
for all orders over $99.99 within the CONTINENTAL USA.
¿Resfriado o Gripe INFLUENZA?RECOMENDACIONES DE VACUNACIÓN FRENTE A LA GRIPE Temporada 2021-2022 INFLUENZA "GRIPE" ¿En que consiste la Vacuna? Nota: se publicó "Prevención y control de la influenza estacional con...
EMS Solutions International |
Background: Previous evidence has found that oseltamivir reduces median time to alleviation of influenza symptoms over placebo by about 1 day. The benefits were greater when treatment was initiated within...
Marco Torres |
Background: Baloxavir (trade name Xofluza) was approved for the treatment of acute, uncomplicated influenza in patients > 12 years of age in October 2018. However, high-quality data has been underwhelming...
Marco Torres |
It remains to be seen whether influenza and COVID-19 will overlap. The actions we take now will determine how well we navigate the coming waves and resulting surges. We’re aiming...
Dr. Howard Ovens |
It remains to be seen whether influenza and COVID-19 will overlap. The actions we take now will determine how well we navigate the coming waves and resulting surges. We’re aiming...
Dr. Howard Ovens |
Article: Uyeki TM et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clin Infect...
Marco Torres |
Background: On October 24th, 2018, Roche, the maker of oseltamivir, announced that the US Food and Drug Administration (FDA) approved Xofluza (baloxavir marboxil) for the treatment of acute, uncomplicated influenza...
Marco Torres |
Your cart
Visit our support center
Expert help & advice
Check your order status
Updates & tracking
Returns & exchanges
All you need to know
Everyday Low Prices
No need to wait for a "sale"
Choose options
